Oragenics Inc (OGEN)
1.03
-0.03
(-2.83%)
USD |
NYAM |
Apr 26, 16:00
1.05
+0.02
(+1.94%)
After-Hours: 20:00
Oragenics Enterprise Value: 3.172M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 3.172M |
April 24, 2024 | 3.306M |
April 23, 2024 | 3.306M |
April 22, 2024 | 3.172M |
April 19, 2024 | 3.485M |
April 18, 2024 | 3.485M |
April 17, 2024 | 3.261M |
April 16, 2024 | 3.261M |
April 15, 2024 | 3.888M |
April 12, 2024 | 3.933M |
April 11, 2024 | 3.933M |
April 10, 2024 | 3.799M |
April 09, 2024 | 4.112M |
April 08, 2024 | 4.381M |
April 05, 2024 | 3.620M |
April 04, 2024 | 3.709M |
April 03, 2024 | 4.336M |
April 02, 2024 | 5.009M |
April 01, 2024 | 4.829M |
March 28, 2024 | 4.874M |
March 27, 2024 | 4.695M |
March 26, 2024 | 4.740M |
March 25, 2024 | 4.784M |
March 22, 2024 | 5.009M |
March 21, 2024 | 5.009M |
Date | Value |
---|---|
March 20, 2024 | 4.650M |
March 19, 2024 | 4.784M |
March 18, 2024 | 4.740M |
March 15, 2024 | 4.695M |
March 14, 2024 | 4.874M |
March 13, 2024 | 4.874M |
March 12, 2024 | 4.829M |
March 11, 2024 | 4.829M |
March 08, 2024 | 4.964M |
March 07, 2024 | 5.054M |
March 06, 2024 | 4.964M |
March 05, 2024 | 4.874M |
March 04, 2024 | 4.964M |
March 01, 2024 | 4.829M |
February 29, 2024 | 2.827M |
February 28, 2024 | 2.796M |
February 27, 2024 | 5.970M |
February 26, 2024 | 8.157M |
February 23, 2024 | 8.527M |
February 22, 2024 | 8.557M |
February 21, 2024 | 8.758M |
February 20, 2024 | 9.790M |
February 16, 2024 | 9.574M |
February 15, 2024 | 9.512M |
February 14, 2024 | 9.112M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-4.262M
Minimum
Mar 27 2023
142.74M
Maximum
Feb 12 2021
22.45M
Average
14.88M
Median
Enterprise Value Benchmarks
Palatin Technologies Inc | 19.88M |
Inogen Inc | 29.68M |
Cyclacel Pharmaceuticals Inc | -1.269M |
Actinium Pharmaceuticals Inc | 125.28M |
MAIA Biotechnology Inc | 53.36M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -12.75M |
Total Expenses (Quarterly) | 12.80M |
EPS Diluted (Quarterly) | -5.48 |
Earnings Yield | -881.0% |
Normalized Earnings Yield | -8561.48 |